| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the hepzatokit.com website. Potential patients, caregivers, and healthcare providers may use the Locator to identify healthcare settings, offering treatment with the HEPZATO KIT.
Sites included on the Locator are accepting inquiries from patients or their physicians seeking potential treatment with HEPZATO KIT. These sites either have or expect to have completed all training and internal approvals necessary to treat a patient subsequent to the normal screening for eligibility.
"The Healthcare Setting Locator, which the Company will update periodically, is an important tool to assist patients, their caregivers, and their healthcare providers, as they consider appropriate treatment options," said Kevin Muir, Delcath's General Manager of U.S. Interventional Oncology. "The previously announced establishment of the permanent J-Code for HEPZATO (J9248) and the launch of the Locator are two important steps in providing information and access to patients for this treatment."
"The Healthcare Settings Locator is a great resource for metastatic uveal melanoma patients. Finding treatments is one of the hardest tasks for a mUM patient. With this Locator, patients can find and coordinate care on their own rather than relying only on the treatments their local physician provides," said Melody Burchett, President of A Cure In Sight, a leading advocacy group for patients with Uveal Melanoma.
The HEPZATO KIT is a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Posted In: DCTH
